Chronic diseases, which often afflict older people and can be controlled but not cured, include heart disease, arthritis, diabetes, stroke, and cancer. Chronic illness burden is increasing internationally as a result of lifestyle changes, physical inactivity, poor diet, and cigarette smoking. Scientists and researchers have been working on a new creative therapeutic strategy in order to provide patients with the greatest curative treatment choice. This can be accomplished by the use of NK cell therapy, which has the potential to elicit a powerful immune response while also fighting cancers.
In 2021, the market for therapeutic uses of Natural Killer Cells had a value of US$ 2.1 billion.
Leading Companies in the Natural Killer Cells Industry:
1. Merck KGaA: Merck KGaA is divided into three divisions: biological sciences, performance materials, and healthcare. Founded 1891. Darmstadt, Germany, serves as the company's headquarters. Merck KGaA receives Pfizer's cancer immunotherapy rights.
2. Bristol-Myers Squibb Company: Bristol-Myers Squibb discovers, develops, and markets pharmaceuticals for a wide range of therapeutic areas, including cardiovascular, cancer, and immunological illnesses. Bristol has a strong concentration on immuno-oncology, where it is a market leader in medication development. Founded 1887. Headquarters are in New York, USA. Bristol Myers Squibb was the ideal partner, bringing the best transaction structure, significant expertise, and a commitment of resources.
3. Glycostem: Creator of allogeneic cell therapies for the treatment of cancer and other diseases, including leukaemia. In order to treat solid tumours and terminal cancer, the company's products are used to expand and differentiate hematopoietic stem and progenitor cells derived from various sources, including umbilical cord blood, bone marrow, and mobilised peripheral blood. This allows patients to remove tumours without undergoing surgery. Founded 2007. Head office in the Netherlands. Cleveland Cord Blood Center's cutting-edge Cleveland Cell Therapy Incubator (CCTI), which specialises in the creation of therapeutic allogeneic off-the-shelf Natural Killer (NK) cells, has signed an agreement with Glycostem Therapeutics B.V. A fully owned division of the Cleveland Cord Blood Centre is CCTI.
4.Sanofi: Greifswald, Germany, is home to four molecules and eight related brands. The asset is focused on two major treatment areas: uro-oncology and gynaecology. Headquarters are in Paris, France. Sanofi and IGM Biosciences Announce Oncology, Immunology, and Inflammation Target Collaboration Agreement.
5. Cytovia Therapeutics: Owner of a biopharmaceutical business with the goal of meeting various oncology-related medical demands. With the use of multispecific antibodies and a small-molecule inhibitor and activator of capsules discovered and developed by the company's unique drug screening technology, patients can fight cancer through stem cell engineering. United States headquarters. Daniel Teper established the business in 2022, and it has its corporate headquarters in Aventura, Florida. - Cytovia Therapeutics, company developing allogeneic "off-the-shelf" gene-edited Natural Killer (NK) and Chimeric Antigen Receptor (CAR)-NK, announced that have entered into a strategic R&D collaboration to develop TALEN® gene-edited iPSC NK and CAR-NK cells.
Definition: A type of immune cell that has granules with enzymes that can kill tumor cells or cells infected with a virus.
